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ABSTRACT
Background: A great interest has been dedicated to the development of non-invasive predictive models in 
UHFHQW\HDUVWRVXEVWLWXWHOLYHUELRSV\IRU¿EURVLVDVVHVVPHQWDQGIROORZXS&URVVHWDOSURSRVHG.LQJ¶VVFRUH
age (years) x aspartate aminotransferase/AST (IU/L) x [international normalized ratio (INR)/platelets (109/L)]. 
7KLVVWXG\DLPVWRLQYHVWLJDWHWKHDFFXUDF\RI.LQJ¶VVFRUHIRUSUHGLFWLQJOLYHU¿EURVLVLQSDWLHQWVZLWKFKURQLF
Hepatitis B. 
Method: )URP)HEUXDU\ XQWLO -XO\  VL[W\ WZRSDWLHQWV FRQ¿UPHG FKURQLF+HSDWLWLV% XQGHUZHQW
Fibroscan in Division of Gastroenterology and Hepatology at Haji Adam Malik Hospital, Medan. Serum 
REWDLQHGDQGDQDO\]HGIRU$67,15DQGSDQFUHRODXU\OWHVW3/7DFWLYLW\DQGWKH.LQJ¶VVFRUHZDVFRPSXWHG
/LYHU¿EURVLVSDWKRORJ\ZDVVWDJHGDFFRUGLQJWRDGH¿QHGV\VWHPRQDVFDOHRI)WR)LQ)LEURVFDQ:HXVHG
SUHGLFWLYHYDOXHVWRDVVHVVWKHDFFXUDF\RI.LQJ¶VVFRUH
Results: .LQJ¶VVFRUHJUHDWHUWKDQRUHTXDOWRLQSUHGLFWHGVLJQL¿FDQW¿EURVLVKDVVHQVLWLYLW\
VSHFL¿FLW\SRVLWLYHSUHGLFWLYHYDOXH339QHJDWLYHSUHGLFWLYHYDOXH139.LQJ¶VVFRUH
JUHDWHUWKDQRUHTXDOWRLQSUHGLFWHGFLUUKRVLVKDVVHQVLWLYLW\VSHFL¿FLW\SRVLWLYH
SUHGLFWLYHYDOXH339QHJDWLYHSUHGLFWLYHYDOXH1397KHYDOLGDWLRQVHWFRQ¿UPHGWKHXWLOLW\RIWKLV
LQGH[DUHDXQGHUUHFHLYHURSHUDWLQJFKDUDFWHULVWLFFXUYHVIRUHDFKQRQVLJQL¿FDQWDQGFLUUKRVLVZDV
(95% CI: 0,545-0,822; p = 0,014) and 0,845 (95% CI: 0,664-1,027; p = 0,006), respectively. 
Conclusion: 7KH.LQJ¶VVFRUHSUHGLFWVFLUUKRVLVJUDGH¿EURVLVLQSDWLHQWVZLWKKLJKDFFXUDF\IRUVLJQL¿FDQW
¿EURVLVWKLVVFRUHGLGQRWVKRZDFFXUDWHUHVXOW
Keywords:.LQJ¶VVFRUH)LEUR6FDQOLYHU¿EURVLVFKURQLF+HSDWLWLV%
ABSTRAK
Latar belakang: Dalam beberapa tahun terakhir ini, perhatian yang besar telah didedikasikan bagi 
pengembangan model prediksi non-invasif dalam mengurangi tingkat kebutuhan biopsi hati untuk penilaian dan 
HYDOXDVL¿EURVLVKDWL&URVVHWDOWHODKPHQJXVXONDQ.LQJ¶VVFRUHGHQJDQPHQJXNXUXVLDWDKXQ[DVSDUWDWH
aminotransferase/AST (IU/L) x [international normalized ratio (INR)/jumlah platelet (109/L)]. Penelitian ini 
EHUWXMXDQXQWXNPHQLODLDNXUDVL.LQJ¶VVFRUHGDODPPHPSUHGLNVLGHUDMDW¿EURVLVKDWLSDGDSDVLHQSHQ\DNLW
hepatitis B kronik. 
Metode: 'DUL)HEUXDUL KLQJJD -XOL  SDVLHQSHQ\DNLW KHSDWLWLV% NURQLNPHQMDODQL ¿EURVFDQGL
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SHPHULNVDDQVHUXP$67,15SDQFUHRODXU\OWHVW3/7VHUWDVHODQMXWQ\DPHQJNDONXODVL.LQJ¶VVFRUH3DWRORJL
¿EURVLVKDWLGLJUDGDVLEHUGDVDUNDQVLVWHPSHQLODLDQ¿EURVFDQGDULVNDOD)VDPSDL)'LJXQDNDQQLODLQLODL
SUHGLNWLIGLDJQRVWLNGDODPPHQLODLDNXUDVL.LQJ¶VVFRUH
Hasil: .LQJ¶VVFRUHPHPLOLNLVHQVLWLYLWDVVHEHVDUVSHVL¿VLWDVQLODLSUHGLNVLSRVLWLI
QLODLSUHGLNVLQHJDWLIGDODPPHPSUHGLNVLVLJQL¿NDQ¿EURVLV8QWXNPHPSUHGLNVLVLURVLV.LQJ¶VVFRUH
PHPLOLNLQLODLDNXUDVL\DQJWLQJJLGHQJDQVHQVLWLYLWDVVHEHVDUVSHVL¿VLWDVQLODLSUHGLNVL
positif 38,5%, nilai prediksi negatif 98%. Nilai area under receiver operating characteristic (AUROC) untuk 
PDVLQJPDVLQJQRQVLJQL¿NDQGDQVLURVLVDGDODK&,S GDQ&,
0,664-1,027; p = 0,006). 
Simpulan: .LQJ¶V6FRUHPHPLOLNLNHPDPSXDQPHPSUHGLNVLVLURVLV¿EURVLVJUDGHSDGDSDVLHQSHQ\DNLW
KHSDWLWLV%NURQLNGHQJDQWLQJNDWDNXUDVL\DQJWLQJJLVHKLQJJDSDVLHQGHQJDQQLODL.LQJ¶VVFRUHWLGDN
membutuhkan biopsi hati lagi.
Kata kunci: .LQJ¶VVFRUH¿EURVFDQ¿EURVLVKDWLSHQ\DNLWKHSDWLWLV%NURQLN
INTRODUCTION
Chronic liver disease was involving a progressive 
destructive and regenerative process that begins 
ZLWKOLYHU¿EURVLVPRVWO\SURJUHVVWROLYHUFLUUKRVLV
and hepatocellular carcinoma. Liver fibrosis was 
caused by chronic damage in liver tissue, related to 
abundant accumulation of extracellular matrix (ECM) 
protein.1,27KHPDLQFDXVHRIOLYHU¿EURVLVZDVFKURQLF
infection of Hepatitis B and C virus, alcoholism, 
autoimmune disease, cholestatic disease, and non-
alcoholic steatohepatitis (NASH). Accumulation 
of ECM protein will damage liver architecture by 
IRUPLQJ¿EURXV FRQQHFWLYH WLVVXH DQGGHYHORSPHQW
of liver nodule. A well-formed nodule stage was 
also known as liver cirrhosis.2/LYHU¿EURVLVZDV D
healing process in response to chronic liver tissue 
injury. Liver cirrhosis detection and staging were 
important in chronic hepatitis patient management.2 
Chronic Hepatitis B was the most common infection 
in chronic hepatitis worldwide. A predictive model 
ZDV GHVLJQHG VSHFL¿FDOO\ IRU FKURQLF+HSDWLWLV %
patients by Shanghai Liver Fibrosis Group (SLFG), 
Hui et al, and Mohamadnejad et al.3,4 However, only 
several of models above that have been validated and 
implemented in clinical situation.3,4 
6LQFHLWKDVEHHQNQRZQWKDW¿EURVLVZDVWKHPDLQ
problem that lead to high morbidity and mortality in 
FKURQLFKHSDWLWLVOLYHU¿EURVLVGHJUHHDVVHVVPHQWZDV
needed to determine the suitable early treatment.5 Liver 
biopsy as an invasive method was still become the 
JROGVWDQGDUGLQGLDJQRVLQJOLYHU¿EURVLV7KHPDLQ
problem was that clinical presentation of the disease 
was vary among patients and not always similar to 
its degree, besides that several patients also refused 
biopsy procedure.5 Limitation in biopsy procedure 
was variation among biopsy result of both intra and 
interobserver, and also a sampling error. There were also 
GLI¿FXOWLHVWRJHWVLPLODUTXDQWLW\LQHDFKOLYHU¿EURVLV
degree groups.6,7%HFDXVHRILWVGLI¿FXOWLHVGXULQJWKLV
LQYDVLYHPHWKRGVHYHUDOVWXGLHVZDVDLPHGWR¿QGD
QRQLQYDVLYHGLDJQRVWLFLQVWUXPHQWIRUOLYHU¿EURVLV5
There were a lot of research to develop any non-
invasive predictive model that strongly correlate to 
OLYHU ¿EURVLV VWDJHV LQ UHFHQW \HDUV1RZDGD\V DQ
LQVWUXPHQWZDV IRXQG WR DVVHVV OLYHU ¿EURVLV QRQ
invasively.4,5,8 This technique was known as ultrasound 
elastography, commercially known as Fibroscan. 
This new imaging technique has been proven to 
assess liver fibrosis degree with high accuracy.4,8 
%XW LWV FRVWZDV KLJK DQG DOVR GLI¿FXOW WR EHFRPH
a routine test in clinical practice. This instrument 
ZDVPRUHVHQVLWLYHWRGHWHUPLQHOLYHU¿EURVLVVWDJHV
E\ FDOFXODWLQJ OLYHU VWLIIQHVV WR LWV ¿EURVLV VFDOH LQ
kilopascal unit (kPa).4,8/LYHU¿EURVLVGHWHUPLQHGE\
)LEUR6FDQZDVVLJQL¿FDQWO\VLPLODUWRLWVUHDO¿EURVLV
stages. This diagnostic accuracy of FibroScan was 
also higher compared to several biochemistry markers 
examination. The advantage of FibroScan was that it is 
done in a short time periode, without any pain, and less 
misinterpretation risk compared to liver biopsy.4,7,8,9 
There has been previous study to investigate the 
FRUUHODWLRQRIOLYHU¿EURVLVGHJUHHZLWK.LQJ¶VVFRUH
in compared to Fibroscan in chronic Hepatitis C 
patients.10 Therefore, we aimed to investigate the 
FRUUHODWLRQEHWZHHQOLYHU¿EURVLVGHJUHHZLWKVLPSOH
QRQLQYDVLYHPHWKRGWRSUHGLFWOLYHU¿EURVLVLQFKURQLF
Hepatitis B infection based on King’s score compared 
to FibroScan, as a daily clinical reference for chronic 
Hepatitis B patients. 
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METHOD
This study was a cross sectional study conducted 
from February to July 2013 located in Internal 
Medicine Department Ward and Polyclinic Haji Adam 
Malik Hospital, Medan, and several gastroenterology 
clinics in Medan. This study has been approved by 
North Sumatra Health Research Ethical Committee. 
Population was all chronic Hepatitis B patients, while 
sample was chronic Hepatitis B patients in ward and 
polyclinic Haji Adam Malik Hospital, Medan, and 
several gastroenterology clinics in Medan. With known 
proportion of chronic Hepatitis B patients in Indonesia 
was 0,36 while in this study was approximately 
0,11, the sample size of this study was 39 patients. 
Inclusion criteria was: (1) Male or female aged > 18 
years; (2) Chronic Hepatitis B patients with positive 
viral marker; and (3) Willing to participate by signing 
informed concent letter. Exclusion criteria was: (1) 
+XPDQ LPPXQRGH¿FLHQF\YLUXV +,9RU+HSDWLWLV
C virus (HCV) coinfection, alcohol consumption of 
> 30 g/day; and (2) Other cause of chronic Hepatitis, 
decompensated liver cirrhosis, and chronic kidney 
failure patients. 
Laboratory examination was done in Clinical 
Pathology Laboratorium in Haji Adam Malik Hospital, 
Medan. King’s score was a non-invasive examination 
using variable: age, platelet count, aspartate 
aminotransferase (AST) level, and international 
normalized ratio (INR). The formula of this score is:
King’s Score = Age (years) x AST (U/L) x 
                         [ INR / Platelet count (109/L)]
.LQJ¶V6FRUH  FLUUKRVLV
±  VLJQL¿FDQW¿EURVLV
.LQJ¶V6FRUH  LQVLJQL¿FDQW¿EURVLV
To measure its diagnostic value, receiving operating 
characteristic (ROC) curve was used to assess its 
VHQVLWLYLW\6HVSHFL¿FLW\6SHSRVLWLYHSUHGLFWLYH
value (PPV), negative predictive value (NPV), 
diagnostic accuracy (DA), positive likelihood ratio 
(LR+), and negative likelihood ratio (LR-) based on 
cut off value in its original journal. Analysis was done 
using SPSS ver 15 software. 
RESULTS
Overall, a total of 62 chronic Hepatitis B patients 
was involved in this study. Clinical characteristic, 
ELRFKHPLVWU\ DQG OLYHU ¿EURVLV GHJUHH LV VKRZQ LQ
Table 1. Mean patient age was 46 years, consist of 39 
male patients (62,9%) and 23 female patients (37,1%). 
All patients was not in decompensated liver cirrhosis 
condition. Table 1 showed a lowest and highest level 
of platelet count (58.000/mm3 and 417.000/mm3, 
respectively), AST level (14 and 124, respectively), and 
INR (0,64 and 2,62 IU/L, respectively). The FibroScan 
result showed a lowest and highest score of 3,8 kPa 
and 67,8 kPa, while King’s score showed 0,7 and 88,2, 
UHVSHFWLYHO\/LYHU¿EURVLVGHJUHHEDVHGRQ)LEUR6FDQ
UHVXOWFODVVL¿HGLQWR¿EURVLV)RIDEVHQWDQG
PLOG¿EURVLV))RI)RIDQG)RI
17,7% from all patients. 
Table 1. Subject characteristic of the study
Variable n (%) Chronis Hepatitis B patients
Patient 
Gender
Male
Female


Age (year) 6'
3ODWHOHW/L) 6'
AST (g/L) 
INR (IU/L) 
FibroScan (kPa) 
King’s Score (score)
Fibrosis (FibroScan)
)
F2
F3
)
35 (56.5)




AST: aspartate aminotransferase; INR: international normalized ratio 
Based on Kolmogorov-Smirnov normality test, age 
and platelet count were normally distributed (mean, 
SD), while other data was nor normally distributed 
PHGLDQPLQPD[PHDVXUHPHQW/LYHU¿EURVLVGHJUHH
was based on Fibroscan, presented as number and 
percentage. 
Cut off value of King’s score and its formula was 
based on its original investigation (Cross et al).10 
&XW RII YDOXH WKDW FRQ¿UPHG FLUUKRVLVZDV> 16,7 
DQGFXWRIIYDOXHWRFRQ¿UPVLJQL¿FDQW¿EURVLVZDV
> 12,2. Predictive value of this model in identifying 
VLJQL¿FDQW¿EURVLVDQGFLUUKRVLVLQFKURQLF+HSDWLWLV%
patients was shown in Table 2. Among 27 patients that 
GLDJQRVHGVLJQL¿FDQW¿EURVLVE\)LEUR6FDQSDWLHQWV
(48,1%) showed a King’s score higher than 12,2. With 
WKDWVFRUHSDWLHQWVFRXOGEHFODVVL¿HGWRQRW
GHYHORSVLJQL¿FDQW¿EURVLV
Cirrhosis cut off value was > 16,7. Five patients 
(83,3%) that have King’s score more than 16,7 from 
total of six patients was diagnosed to have liver 
cirrhosis using FibroScan. With King’s score more than 
DERXWRISDWLHQWVFRXOGEHFODVVL¿HGWRQRW
develop liver cirrhosis. King’s score diagnostic value 
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&ƌ
ĞƋ
ƵĞ
ŶĐ
Ǉ
&ŝďƌŽ^ĐĂŶ ŐƌŽƵƉŝŶŐ
)LJXUH/LYHU¿EURVLVGHJUHHEDVHGRQ)LEUR6FDQ
was further evaluated using area under ROC curve 
(AUROC), LR (+), LR (-), and diagnostic accuracy. In 
SUHGLFWLQJ¿EURVLV$852&ZDVIRU.LQJ¶VVFRUH
)LJXUH2WKHUZLVH LQSUHGLFWLQJVLJQL¿FDQW OLYHU
¿EURVLV$852&IRU.LQJ¶VVFRUHZDV)LJXUH
4). Form this result, although only consist of routine 
laboratory examination, King’s score was accurate and 
well-predictive in cirrhosis prediction. 
6HQVLWLYLW\VSHFL¿FLW\339139/5/5
and accuracy value of this predictive model was shown 
in Table 2. In Table 2, King’s score showed a high 
predictive value to predict liver cirrhosis, and also a 
high sensitivity, high NPV, and low LR (-) so that it 
has lower false negative incidence. Result in King’s 
VFRUHVKRZHGDVHQVLWLYLW\VSHFL¿FLW\
76,5% PPV, 68,9% NPV, 0,54 LR (+), 0,53 LR (-), 
DQGDFFXUDF\WRLGHQWLI\VLJQL¿FDQW¿EURVLVLQ
chronic Hepatitis B patients. King’s score also showed 
DVHQVLWLYLW\VSHFL¿FLW\339
NPV, 0,98 LR (+), 0,96 LR (-), and 85,48% accuracy 
to identify cirrhosis in chronic Hepatitis B patients. 
<ŝŶŐ͛Ɛ ƐĐŽƌĞ ŐƌŽƵƉŝŶŐ
&ƌ
ĞƋ
ƵĞ
ŶĐ
Ǉ
)LJXUH/LYHU¿EURVLVGHJUHHEDVHGRQ.LQJ¶VVFRUHJURXSLQJ
7DEOH3UHGLFWLYHYDOXHRI.LQJ¶VVFRUHPRGHODVSUHGLFWLYHPRGHORIVLJQL¿FDQW¿EURVLVLQFKURQLF+HSDWLWLV%SDWLHQWV
Model
Cut-off 
VLJQL¿FDQW
¿EURVLV
6LJQL¿FDQW)LEURVLV
FibroScan Sen (%) Spe (%) PPV (%)
NPV 
(%) AUROC LR + LR -
Accuracy 
(%)F2-4
n = 27
F0-1
n = 35
King’s Score     88,6 76,5     
6HQVHQVLWLYLW\6SHVSHFL¿FLW\339SRVLWLYHSUHGLFWLYHYDOXH139QHJDWLYHSUHGLFWLYHYDOXH/5SRVLWLYHOLNHOLKRRGUDWLR/5QHJDWLYHOLNHOLKRRGUDWLR
AUROC: area under the ROC curves. 
)LJXUH52&FXUYHRI.LQJ¶VVFRUHLQSUHGLFWLQJVLJQL¿FDQW
¿EURVLVLQFKURQLF+HSDWLWLV%SDWLHQWV
Figure 4. ROC curve of King’s score in predicting liver cirrhosis 
in chronic Hepatitis B patients
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DISCUSSION
There were several previous non-invasive diagnostic 
model in chronic Hepatitis that have been published. 
Most of those diagnostic model was used in chronic 
Hepatitis C patients and only a few in chronic Hepatitis 
B patients.11 Although two last study of FibroTest in 
chronic Hepatitis B patients showed a 0,77 and 0,78 
in AUROC value, those model was using unroutine 
laboratory examination, such as haptoglobin, A2M, 
and apolipoprotein A1. Its complexity and cost reduce 
its utility in daily practice.12
Several predictive model that design for chronic 
Hepatitis B patients was already proposed, but this 
study was still have several unique factors. First, SLFG 
model was designed and validate only for HBeAg 
positive patients with ALT between 2 and 10 times from 
upper limit of normal (ULN), while Mohamadnejad et 
al proposed a formula that only suitable for HBeAg 
negative patients.11 Hui et al only recruited patients 
with HBV DNA > 105 copy/mL and ALT between 
1,5 and 10 from upper limit of normal. In current 
study, patients recruited was all patients with chronic 
Hepatitis B without considering its treatment, HBeAg 
level, ALT, and HBV DNA level. Therefore, this study 
result was more applicable for chronic Hepatitis B 
patients with wider coverage.10,12,13
Second, this predictive model of King’s score 
was based in routine laboratory examination. Platelet 
count, AST, and INR was a routine test that available 
widely in clinical settings, so there were no need of 
extra laboratory examination.10,11,12,13 Previous study 
by Kun Zhou et al showed that accuracy of diagnostic 
PRGHOWKDWFRQVLVWRIURXWLQHWHVWFRPSDUHGWRVSHFL¿F
test such as HA and A2M showed that SLFG model 
and Hepascore was better in identify significant 
¿EURVLV WKDQ )RUQV VFRUH DQG$35, EXW WKH UHVXOW
was insignificant for advanced fibrosis and liver 
cirrhosis.12,14,15,16,17 7KLVUHVXOWVKRZHGWKDWVSHFL¿FWHVW
FRXOGLQFUHDVHLWVVHQVLWLYLW\WRSUHGLFWHDUO\¿EURVLV
process. Otherwise, unroutine test in daily practice 
was reduce its utility for standardization, validation, 
DQGURXWLQHO\GLI¿FXOW 14
Third, King’s score was easy to calculate. Several 
previous model, except APRI, consist of complex 
formula that need a calculator in algoritm calculation.9,12 
This simplicity of King’s score and APRI showed 
that it is clinically easier to be applied. But, APRI 
that previously investigated in chronic Hepatitis C 
patients having one of its indicator, AST, to be proven 
LQVLJQL¿FDQWIRU¿EURVLVLQFLGHQFHLQFKURQLF+HSDWLWLV
B patients, according to Kun Zhou et al.12 This was the 
explanation why APRI has a lower AUROC compared 
to King’s score. 9,12
On the other hand, there were several limitations in 
this study. In this study, not all patients was undergo 
OLYHUELRSV\DQGOLYHU¿EURVLVGHJUHHZDVRQO\EDVHG
on FibroScan (transient elastography), although, not 
shown in this report, ten patients was undergo liver 
biopsy with similar result to FibroScan result.8 In 
Kun Zhou et al, liver biopsy is one of their limitation 
too by explaining that liver biopsy was not the gold 
standard because of the possibility in sampling error 
and observer variability. A prospective analysis 
result was also claimed that the risk of liver biopsy 
failure was > 7 times higher than any diagnostic 
marker.8,12,18 To reduce variability and subjectivity, the 
use of laparoscopic biopsy, FibroScan, or validating 
non-invasive test could help the reliability of liver 
biopsy as gold standard. Other limitation is that this 
study result was validate in the same population and 
in small coverage population.
In Asia countries, chronic Hepatitis B was the 
majority of all chronic liver disease. The main purpose 
RILGHQWLI\LQJ¿EURVLVGHJUHHLQWKRVHSDWLHQWVZDVWR
identify eligble patients for antiviral therapy.19 Based 
RQ$VLDQ3DFL¿F*XLGHOLQH LQ&KURQLF+HSDWLWLV%
Management, liver biopsy was indicated for patients 
aged > 40 years with ALT < 2x ULN and HBV DNA 
> 20.000 IU/mL (HBeAg-positive) or > 2000 IU/mL 
+%H$JQHJDWLYH3DWLHQWVZLWK VLJQL¿FDQW¿EURVLV
was the main candidate for antiviral therapy. Based 
on that guideline, if a candidate have been undergo 
FibroScan, liver biopsy could be skipped. In patients 
with normal ALT and FibroScan result < 6,0 kPa, no 
therapy was indicated, < 7,5 kPa was observed, and 
> 12 kPa should be considered to received therapy.4,15,19
Although most of non-invasive predictive model 
could not accurately assess liver fibrosis degree 
Table 3. Predictive value of King’s score model as predictive model of liver cirrhosis in chronic Hepatitis B patients. 
Model Cut-off (cirrhosis)
Sirosis FibroScan
Sen (%) Spe(%) PPV (%)
NPV 
(%) AUROC LR + LR -
Accuracy 
(%)F4n = 6
F0-3
n = 56
King’s Score  5 8 83,3 85,7 38,5     
6HQVHQVLWLYLW\6SHVSHFL¿FLW\339SRVLWLYHSUHGLFWLYHYDOXH139QHJDWLYHSUHGLFWLYHYDOXH/5SRVLWLYHOLNHOLKRRGUDWLR/5QHJDWLYHOLNHOLKRRGUDWLR
AUROC: area under the ROC curves. 
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EHFDXVH RI GLIIHUHQW¿EURVLV VWDJHV DPRQJSDWLHQWV
those predictive model was having a good accurate 
YDOXHLQSUHGLFWVLJQL¿FDQW¿EURVLV7KHPDLQUROHRI
predictive model was to reduce liver biopsy procedure 
IRUVLJQL¿FDQW¿EURVLVDQGOLYHUFLUUKRVLVLGHQWL¿FDWLRQ
but not for totally replace liver biopsy.11,12,13,14 Using 
optimized cut-off core form King’s score, it is 
expected that further livver biopsy needs wa reduced. 
Furthermore, a combination of several predictive 
model and invasive diagnostic technique could bring 
this diagnostic tools into higher level.10 Combination 
of both FibroScan and King’s score was an intersting 
method in chronic Hepatitis B patients management. 
But it has been known that, in daily clinical practice, 
priority should be given into model that have been 
validate in large scale study, because of its accuracy 
could be interfered by different etiologies, populations, 
and methods.10,12
CONCLUSION
King’s score has the ability to predict cirrhosis 
¿EURVLVJUDGHLQFKURQLF+HSDWLWLV%SDWLHQWVZLWK
high accuracy, so that patients with King’s score > 16,7 
did not need to undergo liver biopsy. Otherwise, for 
VLJQL¿FDQW¿EURVLVWKLVPRGHOGLGQRWVKRZDQDFFXUDWH
result. King’s score as non-invasive predictive model 
for liver cirrhosis in chronic Hepatitis B patients have 
a high accuracy. A further study was needed to validate 
this result in a larger scale with different population.
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